Publications by authors named "Pousa I"
Introduction: Certolizumab pegol (CZP) is an anti-tumor necrosis factor alpha (TNFα) approved for the treatment of moderate to severe plaque psoriasis (PSO). However, data on its real-world use is currently limited. The objective of this study was to describe the 1-year real-world effectiveness of CZP, its impact on health-related quality of life (HRQoL), and safety outcomes in patients with moderate to severe PSO in multi-country settings.
View Article and Find Full Text PDFBreast cancer (BC) is the second most cause of central nervous system (CNS) metastases. Studies report that almost one third of patients (pts) with triple-negative, one-third with human epidermal growth factor receptor 2 (HER2)-positive and 15% of those with hormone receptor-positive, HER2-negative metastatic breast cancer will develop brain metastases. It is known that the development of symptomatic brain metastases in women with advanced breast cancer is associated with poor prognosis, irrespective of local and systemic treatments.
View Article and Find Full Text PDFLittle is known about the prediction of atrial fibrillation (AF) risk scores in patients with cancer. The aim of this study was to assess the predictive ability of the CHADS-VASc and HAS-BLED scores in patients with AF and cancer. Overall, 16,056 patients with AF diagnosed between 2014 and 2018 from a Spanish health area, including 1,137 patients with cancer, were observed during a median follow-up of 4.
View Article and Find Full Text PDFArticle Synopsis
- ACE inhibitors (ACEi) and angiotensin II receptor blockers (ARB) show similar survival rates in heart failure patients with low ejection fraction, but their effectiveness in those with preserved ejection fraction post-acute coronary syndrome (ACS) is unclear.
- A study of 3,006 patients with preserved LVEF (≥40%) after an ACS found no significant differences in outcome measures like mortality and heart failure when comparing ACEi and ARB treatments over an average follow-up of 3.6 years.
- The results suggest that there is no prognostic advantage of using ACEi over ARB or vice versa in this patient population, highlighting the need for further studies to validate these findings.
Article Synopsis
- The study analyzed the risks of recurring ischemia and bleeding in patients treated for acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI) over the first year after the procedure.
- Two large registries, BleeMACS and RENAMI, were used to compare the average daily ischemic risk (ADIR) and average daily bleeding risk (ADBR) among nearly 20,000 patients receiving different antiplatelet therapies.
- Results showed that while ADIR was generally greater than ADBR in the initial weeks post-PCI (especially for severe cases), this trend shifted, with higher bleeding risks found in specific groups like non-ST-segment elevation ACS patients and those on ticagrelor after three months
Background: Lung (LC), prostate (PCa) and colorectal (CRC) cancers are the most incident in males worldwide. Despite recent advances, optimal population-based cancer screening methods remain an unmet need. Due to its early onset, cancer specificity and accessibility in body fluids, aberrant DNA promoter methylation might be a valuable minimally invasive tool for early cancer detection.
View Article and Find Full Text PDFArticle Synopsis
- The PRECISE-DAPT and PARIS risk scores were created to help doctors decide on the best duration for dual antiplatelet therapy (DAPT) after heart procedures, but these scores were not tested in patients with acute coronary syndrome (ACS) using recent medications like prasugrel or ticagrelor.
- A study involving 4,424 ACS patients who had percutaneous coronary interventions was conducted, measuring how well these risk scores predicted major bleeding and ischemic events during an average follow-up of 14 months.
- The findings showed that PRECISE-DAPT was more effective in predicting major bleeding incidents, while the PARIS ischemic risk score was better at predicting ischemic
Article Synopsis
- This study compares the effectiveness and safety of clopidogrel, prasugrel, and ticagrelor in over 19,000 patients with acute coronary syndrome undergoing PCI and looks at the risks of ischemic events and bleeding over time.
- Results show prasugrel leads to significantly lower rates of net adverse clinical events and major adverse cardiovascular events compared to clopidogrel, while ticagrelor also reduces major adverse cardiovascular events but has a higher bleeding risk.
- The analysis indicates that clopidogrel’s risk profile peaks at 3 months for ischemic events while prasugrel maintains a balance between ischemia and bleeding, and ticagrelor consistently reduces heart attacks over
Article Synopsis
- The text discusses the significance of the first author's name in scholarly works.
- It highlights how the first author typically represents the main contributor to the research or study.
- The importance of proper citation and recognition in academic settings is emphasized throughout.
Background: Limited data are available concerning differences in clinical outcomes for real-life patients treated with ticagrelor versus prasugrel after percutaneous coronary intervention (PCI).
Objective: Our objective was to determine and compare the efficacy and safety of ticagrelor and prasugrel in a real-world population.
Methods: RENAMI was a retrospective, observational registry including the data and outcomes of consecutive patients with acute coronary syndrome (ACS) who underwent primary PCI and were discharged with dual antiplatelet therapy (DAPT) between January 2012 and January 2016.
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
Eur J Prev Cardiol
May 2020
Article Synopsis
- The study investigates the effectiveness of different durations of dual antiplatelet therapy (DAPT) using prasugrel or ticagrelor in patients with acute coronary syndromes who underwent percutaneous coronary intervention, as previous research primarily focused on clopidogrel.
- Researchers analyzed data from 4424 patients, categorizing them into three groups based on DAPT duration: less than 12 months, exactly 12 months, and more than 12 months, to assess net adverse clinical events (NACEs) and major adverse cardiac events (MACEs).
- Findings showed that patients on 12 months or longer of DAPT had a significantly lower risk of NACEs and MACEs compared to those receiving less than 12
Background: Breast (BrC), colorectal (CRC) and lung (LC) cancers are the three most common and deadly cancers in women. Cancer screening entails an increase in early stage disease detection but is hampered by high false-positive rates and overdiagnosis/overtreatment. Aberrant DNA methylation occurs early in cancer and may be detected in circulating cell-free DNA (ccfDNA), constituting a valuable biomarker and enabling non-invasive testing for cancer detection.
View Article and Find Full Text PDFArticle Synopsis
- - The study assessed the occurrence and predictors of major bleeding in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) and were treated with prasugrel or ticagrelor.
- - Out of 4424 patients, 1.8% experienced significant bleeding after about 14 months, which was linked to higher rates of major adverse cardiovascular events (MACE) and death.
- - Older adults (over 75 years) and women were identified as independent risk factors for major bleeding, suggesting a need for personalized antiplatelet therapy strategies in these groups.
Introduction: Ticagrelor and prasugrel are recommended as first line therapy in patients with acute coronary syndromes (ACS). However, patients with anemia are commonly treated with clopidogrel in routine clinical practice. The RENAMI registry (REgistry of New Antiplatelet therapy in patients with acute Myocardial Infarction) included ACS patients treated with prasugrel or ticagrelor at hospital discharge.
View Article and Find Full Text PDFBackground: Infliximab and adalimumab effectiveness might be related with changes in angiogenic factors. The aim of the study was to compare the concentrations of angiogenic proteins in patients with inflammatory bowel disease (IBD) and healthy controls and to analyze changes in the levels during infliximab and adalimumab treatment.
Methods: A prospective case-control study was conducted in 37 patients with IBD starting treatment with infliximab (16 with Crohn's disease and 6 with ulcerative colitis) or adalimumab (15 with Crohn's disease) and 40 control subjects.
Breast cancer afflicts more than 1.3 million people worldwide and is the main cause of cancer-related deaths among women. Many efforts are underway to develop new therapeutic and biomarker strategies for the management of this disease.
View Article and Find Full Text PDFAims: The aim of this study was to compare angiogenic factors in serum levels of active ulcerative colitis (UC) patients and in healthy controls, and to analyze these angiogenic levels depending on the achievement of remission after oral corticosteroid treatment throughout treatment, and according to the Truelove-Witts activity index.
Methods: Blood samples were collected from 13 patients receiving oral corticosteroids for treatment of UC flares at three different intervals--baseline, during, and after treatment--and from 26 healthy controls. Vascular endothelial growth factor (VEGF), placental growth factor (PlGF), VEGF receptor 1 (VEGFR1), angiopoietins (Ang) 1 and 2, and its receptor Tie2 were assayed by ELISA.
Objective: Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD) treated with 5-aminosalicylates (5-ASA). Our aim was to conduct a retrospective study of IBD patients, both with and without 5-ASA treatment, who underwent regular evaluation of renal function over a 4-year period.
Methods: Serum creatinine was measured before the start of 5-ASA therapy, and thereafter yearly up to 4 years.
Both ulcerative colitis and Crohn's disease, the two major forms of inflammatory bowel diseases, are recognized, at the moment, as perplexing and challenging clinical entities, in which several molecules and cell types are implicated. Recent molecular evidence proposes the intestinal microvascular remodelling or angiogenesis, as a phenomenon implicated in the pathogenesis of these chronic inflammatory disorders, together with other proposed theories involved in the pathogenesis of inflammatory bowel diseases, such as genetic, microbacterial and immune factors. Intestinal damage is followed by a physiological angiogenesis, but the abnormal expression of pro- and anti-angiogenic molecules and the changes of vascular cell types could reflect a pathological vascular remodelling.
View Article and Find Full Text PDFBackground: The purposes of this study were to determine soluble angiogenic factors in Crohn's disease (CD) patients and to compare these factors according to the pathological behavior of the disease in order to establish a possible relationship with its evolution in patients with CD.
Methods: Blood samples were collected from 70 patients with CD, grouped according to their phenotypic behavior, and from 30 healthy controls. Vascular endothelial growth factor (VEGF), placental growth factor (PlGF), angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), and their cognate receptors [VEGFR1, VEGFR2, and angiopoietin receptor tyrosine kinase (Tie2)] were assayed by ELISA.
Background: The aim of the study was to evaluate the incidence of abnormality of liver tests (LTs) or hepatotoxicity in a large group of inflammatory bowel disease (IBD) patients and, specifically, to assess the incidence of azathioprine (AZA)/mercaptopurine (MP)-induced liver injury in a long-term follow-up study.
Methods: All consecutive IBD patients followed for at least 5 years were included in this retrospective study. LTs including alanine transaminase, aspartate transaminase, alkaline phosphatase, gamma-glutamyl transferase, and bilirubin were periodically monitored.
The formation of new blood vessels seen in conditions commonly associated with Helicobacter pylori (H. pylori) infection, including gastritis, peptic ulcer, and gastric carcinoma, prompts consideration of a potential relationship between mucosal colonization by this organism and the angiogenic process. H.
View Article and Find Full Text PDF